Orforglipron for Weight Loss
The first oral GLP-1 that does not require an empty stomach, a 30-minute wait, or a specific time of day. FDA approved April 2026.
Reviewed by GlobalGLP1 editorial team • Drug facts last checked August 2026 • Sources: FDA prescribing information, peer-reviewed clinical trials
Overview
Orforglipron is the active ingredient in Foundayo, the first daily pill GLP-1 that you can take any time of day, with or without food or water. The FDA approved it in April 2026 for chronic weight management in adults with obesity or with overweight plus a weight-related health condition. Unlike oral semaglutide (Rybelsus), which requires an empty stomach and a 30-minute wait before eating or drinking, Foundayo works as a regular small-molecule pill. In the ATTAIN-1 trial, people on the highest dose lost about 12.4% of their body weight over 72 weeks. It is made by Eli Lilly, the same company behind Mounjaro and Zepbound.
How Orforglipron Works
Orforglipron copies the same gut hormone (GLP-1) that powers Wegovy and Ozempic, but with a key difference: it is a small-molecule drug, not a peptide. Peptides like semaglutide are large fragile molecules that the stomach normally destroys, which is why Wegovy and Ozempic are injected, and why oral semaglutide (Rybelsus) needs an empty stomach to absorb. Small molecules absorb reliably no matter what is in your stomach, so Foundayo can be taken any time of day. Once in the bloodstream, it activates GLP-1 receptors in the brain to reduce appetite, slows how fast your stomach empties, and helps the pancreas release insulin after meals. Most people notice reduced appetite within the first few weeks.
FDA Approval
Foundayo
Chronic weight management in adults
0.8, 2.5, 5.5, 9, 14.5, and 17.2 mg once-daily tablets (escalating dose; 17.2 mg is the maintenance dose)
How You Take It
The full dose build-up typically takes a few months. Foundayo is the only GLP-1 pill that does not require an empty stomach, a specific time of day, or a waiting period before food or water. You can take it with breakfast, at bedtime, whenever fits your routine. Picking a consistent time each day helps you remember.
How Much Weight You Can Lose
In the ATTAIN-1 Phase 3 trial, people on the highest dose (17.2 mg) lost an average of 12.4% of their body weight over 72 weeks, compared to 0.9% with placebo, counting people who stayed on treatment. Counting everyone who started, the figure for the same dose was 11.1%. Across all approved tablet doses, the FDA label reports average weight loss of 7.4% to 11.1%. For a 200-pound person on the highest dose, 12.4% is roughly 25 pounds. Counting everyone who started, that 11.1% is less than injectable Wegovy at about 14.9% and Zepbound at about 20.9%, but more than older oral options. The trade-off is convenience: a daily pill instead of a weekly shot.
Side Effects
Common Side Effects
- Nausea (most common during dose increases, usually eases over a few weeks)
- Constipation (common, often helped by fluids and fiber)
- Diarrhea (typically mild and short-lived)
- Vomiting (most common in the first weeks, drops off after the first month)
- Indigestion and heartburn (mild for most people)
- Abdominal pain (usually mild)
- Headache
- Belching and gas
- Fatigue (often improves as your body adjusts)
- Hair thinning (reported by some patients, usually temporary)
Rare but Serious
- Pancreatitis (rare)
- Gallbladder disease
- Thyroid C-cell tumors (boxed warning, observed in rodents)
- Acute kidney injury (linked to dehydration from severe vomiting or diarrhea)
- Hypoglycemia (when combined with insulin or sulfonylureas)
- Allergic reactions
- Breathing food or liquid into the lungs during surgery under general anesthesia or deep sedation. These drugs slow the stomach down, so tell your surgeon, anesthetist and dentist that you take one before any planned procedure
- Worsening of diabetic eye disease in people with type 2 diabetes who already have retinopathy. The label asks for monitoring; this is not described as a risk for people without diabetes
Managing side effects: Stomach side effects are most common during the first weeks and around each dose increase, then ease as your body adjusts. The slow build-up exists for this reason. Eat smaller meals, stay hydrated (especially important with Foundayo because dehydration from GI side effects can hurt the kidneys), and avoid greasy or very rich foods. If nausea is bad enough that you cannot keep fluids down, contact your provider. They can slow or pause the dose escalation.
Orforglipron Cost & Savings (2026)
Savings programs: Eli Lilly offers a Foundayo Savings Card for commercially insured patients (as low as $25/month for eligible patients whose insurance covers it). LillyDirect may carry direct-pay tablets at a discount once supply stabilizes. Medicare and Medicaid patients are not eligible for the commercial savings card.
Who Should Not Take Orforglipron
- Personal or family history of medullary thyroid carcinoma (MTC)
- A rare condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Allergy to orforglipron or any ingredient in Foundayo
- Pregnancy or planning to become pregnant
- History of inflamed pancreas (pancreatitis), use with caution
- Severe stomach or intestinal disease (gastroparesis)
Heart Health
The ACHIEVE-4 trial is the longest Phase 3 study of orforglipron run so far. It evaluated patients with type 2 diabetes and showed consistent improvements across cardiometabolic measures (blood pressure, lipids, blood sugar) along with a heart-safety profile in line with other GLP-1 medications. A dedicated cardiovascular outcomes trial (similar to Wegovy SELECT) is still ongoing.
What this means for you: Foundayo has not yet been shown to reduce heart attacks or strokes the way Wegovy has. If you have obesity plus existing heart disease and need a GLP-1 specifically for heart protection today, Wegovy is the only one with that FDA label. Foundayo is a strong choice if pill-vs-shot is the deciding factor.
What to Expect, Month by Month
Most patients notice decreased hunger and smaller portion sizes. Some early nausea is common.
Measurable weight loss begins as the dose escalates to 14.5 mg. Average 2-4% body weight lost during escalation.
On the full 17.2 mg dose. Steady weight loss of about 1 pound per week. GI side effects have usually settled.
Average 8-12% body weight lost. Blood pressure, cholesterol, and blood sugar improvements measurable.
Weight loss plateau near 12.4% average. Maintenance phase begins.
Other Medications to Watch
Can cause dangerously low blood sugar when combined. Your doctor will usually reduce your insulin or sulfonylurea dose when starting Foundayo.
Foundayo slows digestion, which can change how other oral medications absorb. Less of an issue than with injected GLP-1s because the effect is milder, but tell your prescriber about every drug you take.
Slower digestion can change how warfarin absorbs. Your doctor should check your clotting levels (INR) more often when starting Foundayo or changing your dose.
The FDA label tells prescribers to advise anyone on birth control pills to switch to a non-oral method, or add a barrier method such as condoms, for 30 days after starting Foundayo and for 30 days after each dose increase. This is not optional advice in the label, and Foundayo may cause fetal harm. Methods that are not swallowed, such as the patch, ring, implant, injection or IUD, are not affected.
Special Situations
Do not use during pregnancy. Stop Foundayo well before trying to conceive. Animal studies showed harm to the fetus.
No dose change needed at any level, including end-stage kidney disease. Separately, and for everyone rather than kidney patients alone, the label warns that severe vomiting or diarrhea can dehydrate you enough to injure the kidneys, so stay well hydrated, especially during dose increases.
Foundayo is not recommended if you have severe liver impairment (Child-Pugh Class C). That is the wording the label itself uses, in its summary box, and it is not a data gap. No dose change is needed for mild or moderate.
A subgroup analysis of ATTAIN-1 and ATTAIN-2 showed adults 65 and older lost up to 13% of body weight with Foundayo. No dose change needed, but watch for dehydration since GI side effects can hit older adults harder.
Not currently FDA-approved for adolescents. Studies in younger populations are planned.
What Happens If You Stop
No trial has stopped Foundayo and measured what happens, so there is no figure for this drug the way there is for Wegovy and Zepbound, where roughly two thirds of the lost weight came back within a year. What has been studied is close to the reverse: in the ATTAIN-MAINTAIN trial, people who had lost weight on Wegovy or Zepbound switched to Foundayo and held nearly all of it over 52 weeks. That shows Foundayo can hold a loss; it does not tell you what happens when you stop taking it. Regain after stopping is the pattern for every drug in this class, so expect it until there is evidence otherwise.
How to make stopping easier: Build sustainable eating and movement habits while on the medication so you have a foundation when you stop. Some patients transition to a lower maintenance dose long-term, which is easier and cheaper with a daily pill than with weekly injections. Talk with your prescriber before stopping suddenly.
Orforglipron FAQs
Both are pills, but Foundayo is a small-molecule drug and Rybelsus is an oral version of the injected peptide semaglutide. The practical difference: Foundayo works at any time of day, with or without food or water, while Rybelsus must be taken on an empty stomach with no food, drink, or other medications for at least 30 minutes after. Foundayo is also approved for weight loss; Rybelsus is approved for weight loss as well but produces less weight loss on average.
In the ATTAIN-1 trial, people on the highest FDA-approved dose lost an average of 12.4% of their body weight over 72 weeks. About 1 in 3 lost more than 15%. Lower doses produced 7.8% (5.5 mg) and 9.3% (14.5 mg) weight loss. That is less than injectable Wegovy or Zepbound, but more than older oral options.
The list price runs roughly $700 to $1,000 per month at retail pharmacies. With commercial insurance and the Lilly savings card, eligible patients may pay as little as $25 per month. Medicare and Medicaid patients are not eligible for the commercial savings card.
If you are losing weight steadily on an injectable and tolerating it well, there is no medical reason to switch. Foundayo is the better choice if you cannot tolerate needles, have trouble keeping injection pens refrigerated, travel frequently, or have run into supply issues. In trials, people who switched from injectable GLP-1s to oral Foundayo were able to maintain their weight loss.
Nausea, constipation, diarrhea, vomiting, and abdominal pain are the most common. They tend to be worst during the first few weeks and when your dose increases, then settle down. A small number of patients report hair thinning, which is usually temporary. Severe vomiting or diarrhea can lead to dehydration and rare cases of kidney injury, so contact your provider if you cannot keep fluids down.
The FDA approved Foundayo in April 2026 and it became commercially available shortly after. Supply has been ramping through 2026 as Lilly scales manufacturing. Some pharmacies may have limited stock of certain doses during the rollout.
Looking for a Clinic?
Orforglipron is a new medication. While our directory does not yet have confirmed Orforglipron prescribers, many GLP-1 clinics will prescribe it for eligible patients.
Browse GLP-1 Clinics →Related Orforglipron resources
Looking for Orforglipron?
Orforglipron is a new medication. Our directory does not yet have confirmed Orforglipron prescribers, but many of our 3,318 GLP-1 clinics will prescribe it for eligible patients. Browse all clinics or ask any GLP-1 prescriber about availability.
References
Every figure on this page comes from one of the following. Prescribing information is linked on DailyMed, which serves the current label rather than a snapshot of an old one. Trials are linked by DOI.
- Foundayo (orforglipron) tablets: prescribing information
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1) The 72-week trial behind the ~11-12.4% figures.
Drug facts on this page last checked against these sources August 2026.
Medical Disclaimer: This guide is for informational purposes only and is not medical advice. All clinical data is sourced from FDA prescribing information and published peer-reviewed trials. Individual results vary. Always consult a qualified healthcare provider before starting, stopping, or switching any medication.